TW201422596A - 新穎噁唑啶酮化合物 - Google Patents
新穎噁唑啶酮化合物 Download PDFInfo
- Publication number
- TW201422596A TW201422596A TW102138950A TW102138950A TW201422596A TW 201422596 A TW201422596 A TW 201422596A TW 102138950 A TW102138950 A TW 102138950A TW 102138950 A TW102138950 A TW 102138950A TW 201422596 A TW201422596 A TW 201422596A
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- group
- alkyl
- compound
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190319 | 2012-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201422596A true TW201422596A (zh) | 2014-06-16 |
Family
ID=47143594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102138950A TW201422596A (zh) | 2012-10-29 | 2013-10-28 | 新穎噁唑啶酮化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9611232B2 (enExample) |
| EP (1) | EP2912034B1 (enExample) |
| JP (1) | JP6216385B2 (enExample) |
| KR (1) | KR20150075091A (enExample) |
| CN (1) | CN104781256B (enExample) |
| AR (1) | AR093168A1 (enExample) |
| AU (1) | AU2013339607A1 (enExample) |
| BR (1) | BR112015003996A2 (enExample) |
| CA (1) | CA2879249A1 (enExample) |
| CL (1) | CL2015000906A1 (enExample) |
| CO (1) | CO7170170A2 (enExample) |
| CR (1) | CR20150159A (enExample) |
| EA (1) | EA026161B1 (enExample) |
| IL (1) | IL237331A0 (enExample) |
| IN (1) | IN2015DN00961A (enExample) |
| MA (1) | MA38135B1 (enExample) |
| MX (1) | MX2015002399A (enExample) |
| PE (1) | PE20150775A1 (enExample) |
| PH (1) | PH12015500292A1 (enExample) |
| SG (1) | SG11201500585XA (enExample) |
| TW (1) | TW201422596A (enExample) |
| UA (1) | UA114649C2 (enExample) |
| WO (1) | WO2014067861A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| KR102865950B1 (ko) | 2019-03-22 | 2025-09-30 | 사니오나 에이/에스 | 신규의 칼륨 채널 억제제 |
| EP4217065A1 (en) * | 2020-09-22 | 2023-08-02 | Saniona A/S | Novel potassium channel inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
| DE3687870T2 (de) * | 1985-09-09 | 1993-08-19 | Otsuka Pharma Co Ltd | 2-oxa-isocephemverbindungen, sie enthaltende zusammensetzungen und verfahren zu deren herstellung. |
| CA2095429A1 (en) * | 1990-11-06 | 1992-05-07 | Paul E. Bender | Imidazolidinone compounds |
| DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| WO1997031892A1 (fr) * | 1996-03-01 | 1997-09-04 | Sankyo Company, Limited | Derives d'acide hydroxamique |
| AU760250B2 (en) * | 1998-12-04 | 2003-05-08 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| EP1818326A1 (en) * | 2000-01-20 | 2007-08-15 | Eisai R&D Management Co., Ltd. | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds |
| JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
| CA2429308C (en) * | 2000-11-22 | 2010-09-21 | Bayer Aktiengesellschaft | Novel lactam-substituted pyrazolopyridine derivatives |
| CA2575003C (en) | 2004-07-29 | 2010-02-16 | Merck & Co., Inc. | Potassium channel inhibitors |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
| US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
| WO2007109098A2 (en) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| AR074558A1 (es) * | 2008-12-12 | 2011-01-26 | Solvay Pharm Bv | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 |
| WO2010123997A1 (en) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Carbacephem beta-lactam antibiotics |
-
2013
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Withdrawn
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/en not_active Not-in-force
- 2013-10-25 CA CA2879249A patent/CA2879249A1/en not_active Abandoned
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/en not_active Ceased
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MA38135A2 (fr) | 2016-11-30 |
| JP6216385B2 (ja) | 2017-10-18 |
| AR093168A1 (es) | 2015-05-20 |
| PE20150775A1 (es) | 2015-05-21 |
| US9611232B2 (en) | 2017-04-04 |
| IN2015DN00961A (enExample) | 2015-06-12 |
| AU2013339607A1 (en) | 2015-02-05 |
| JP2015535231A (ja) | 2015-12-10 |
| MA38135B1 (fr) | 2018-11-30 |
| CR20150159A (es) | 2015-04-30 |
| EP2912034B1 (en) | 2017-05-31 |
| WO2014067861A1 (en) | 2014-05-08 |
| CN104781256A (zh) | 2015-07-15 |
| CA2879249A1 (en) | 2014-05-08 |
| BR112015003996A2 (pt) | 2017-07-04 |
| EA201590729A1 (ru) | 2015-07-30 |
| CL2015000906A1 (es) | 2015-09-11 |
| CN104781256B (zh) | 2017-09-29 |
| UA114649C2 (uk) | 2017-07-10 |
| US20150246894A1 (en) | 2015-09-03 |
| KR20150075091A (ko) | 2015-07-02 |
| SG11201500585XA (en) | 2015-04-29 |
| CO7170170A2 (es) | 2015-01-28 |
| HK1207632A1 (en) | 2016-02-05 |
| IL237331A0 (en) | 2015-04-30 |
| EP2912034A1 (en) | 2015-09-02 |
| MX2015002399A (es) | 2015-06-10 |
| PH12015500292A1 (en) | 2015-04-20 |
| EA026161B1 (ru) | 2017-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11084784B2 (en) | ROR-gamma modulators and uses thereof | |
| TWI429642B (zh) | 用於治療與醯基coA-二醯基甘油醯基轉移酶1活性有關聯之病症之化合物，包含其之醫藥組合物及其用途 | |
| JP5180099B2 (ja) | 置換イミダゾール誘導体、組成物ならびにｐｔｐアーゼ阻害剤としての使用方法 | |
| SG195020A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
| CN101641346B (zh) | 作为mglur2拮抗剂的吡啶和嘧啶衍生物 | |
| JP3103845B2 (ja) | １，２，４−オキサジアゾリルフェノキシアルキルイソオキサゾール類及び抗ウイルス薬としてのそれらの用途 | |
| HRP960272A2 (en) | Heterocyclic compounds | |
| CA3013927C (en) | Halo-substituted piperidines as orexin receptor modulators | |
| JP2004525965A (ja) | ｍＧｌｕＲ２アンタゴニストＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体 | |
| JP2021513982A (ja) | Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びそれらの使用の方法 | |
| CA3047002A1 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| AU2023312202A1 (en) | 1,3,4-oxadiazole derivatives as selective histone deacetylase 6 inhibitors | |
| TW200922585A (en) | Amino 1,2,4-triazole derivatives as modulators of mGluR5 | |
| TWI527808B (zh) | 乙炔基衍生物 | |
| CN104781256B (zh) | 3，4‑双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途 | |
| CN101094837A (zh) | 新颖β－激动剂、其制备方法以及作为药物的用途 | |
| WO1999024425A1 (en) | Benzimidazole derivatives and pharmaceutically acceptable salts thereof | |
| EP1954692A1 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| JP2025517513A (ja) | Ｔｒｐｍ３媒介性障害を治療するための新たな誘導体 | |
| HK1207632B (en) | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel | |
| TW202613091A (zh) | 乳酸脫氫酶抑制劑、包含該抑制劑的組合物及其使用方法 | |
| CN101115721A (zh) | 茚基衍生物和它们在治疗神经疾病中的用途 |